Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.02.2013 | main topic

Efficacy and safety of Echinaforce® in respiratory tract infections

verfasst von: PD Dr. med. Dr. h. c. Andreas Schapowal

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2013

Einloggen, um Zugang zu erhalten

Summary

Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment.
Vorheriger Artikel Besserung der Symptome einer leichten Schilddrüsenüberfunktion mit einem Trockenextrakt aus Wolfstrappkraut (Thyreogutt® mono)
Nächster Artikel Erratum to: Update on denosumab in postmenopausal osteoporosis—recent clinical data
Literatur
1.
Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. Arch Fam Med. 2000;9(90):913–22.PubMedCrossRef
2.
Fendrick AM. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am J Ther. 2003;10:193–202.PubMedCrossRef
3.
Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey 1996. In: Vital and Health Statistics Series 10. Data from the National Health Survey; 1999. pp. 1–203.
4.
Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494.PubMedCrossRef
5.
Johnston SL. Problems and prospects of developing effective therapy for common cold viruses. Trends Microbiol. 1997;5(2):58–63.PubMedCrossRef
6.
Jefferson T. Mistaken Identity: seasonal influenza versus influenza-like illness. Clin Evid. 2009;10:1-4. http://​www.​ clinicalevidence.com/x/mce/file/05-10-09.pdf.
7.
Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310:1225–9.PubMedCrossRef
8.
Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardised Echinacea, a potent antiviral herbal extract. Antiviral Res. 2009;83:165–70.PubMedCrossRef
9.
Pleschka S, Stein M, Schoop R, et al. Anti-viral properties and mode of action of standardised Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J. 2009;6:197.PubMedCrossRef
10.
Schapowal A. The triple action of the herbal medicine Echinaforce in the treatment of cold and flu-like infections. Swiss J Integr Med. 2011;23:1–5.CrossRef
11.
Bonnet F, Lewden C, May T, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37:482–7.PubMedCrossRef
12.
Ritchie MR, Gertsch J, Klein P, et al. Effects of Echinaforce® treatment on ex vivo-stimulated blood cells. Phytomed. 2011;18(10):826–31.CrossRef
13.
Jawad M, Schoop R, Suter A, et al. Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2012. doi:10.1155/2012/841315.
14.
Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. JHSB. 1983;24:385–96.
Metadaten
Titel
Efficacy and safety of Echinaforce® in respiratory tract infections
verfasst von
PD Dr. med. Dr. h. c. Andreas Schapowal
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0166-0

Weitere Artikel der Ausgabe 3-4/2013

Herbal triplet in treatment of nervous agitation in children

  • Open Access
  • main topic

Sulforaphane and related mustard oils in focus of cancer prevention and therapy

  • main topic

Comfrey root: from tradition to modern clinical trials

  • Open Access
  • main topic

Erratum to: Update on denosumab in postmenopausal osteoporosis—recent clinical data

  • Erratum

Besserung der Symptome einer leichten Schilddrüsenüberfunktion mit einem Trockenextrakt aus Wolfstrappkraut (Thyreogutt® mono)

  • themenschwerpunkt

Candelabra Aloe (Aloe arborescens) in the therapy and prophylaxis of upper respiratory tract infections: traditional use and recent research results

  • main topic